HBM Holdings boosts shareholder value through repurchases, expansion

HBM Holdings (HKEX: 2142) announced progress on its share repurchase plan, having already bought back shares worth nearly HK$10 million as of February 7, 2025 and a total of 5,870,000 Shares in 2023 and 2024. Executive Director Dr. Jingsong Wang has also increased his shareholding, reflecting his confidence in the company's intrinsic value. The company's strong financial position, with HK$1.425 billion in cash reserves as of June 30, 2024, supports its strategic collaborations, including those with Windward Bio, Kodiak Sciences, Candid Therapeutics and Invetx. HBM notes that the collaborations are for immunological diseases, ophthalmic diseases, next-generation T-cell Engager and animal health respectively. HBM is signaling the move represents diversification and scalability.